Search Follow us

quantum genomics

1 - 11 of 11
Sort by: popularity | newest
Page  of 1
Windar Photonics

Good progress establishing platform for growth

Flash note | Alternative Energy | 27 Jun 2017

During FY16 Windar took some important strategic steps in rolling out its innovative LiDAR: implementing additional functionality to enlarge the addressable market and modifying its sales channels to focus on the IPP market. While y-o-y revenue growth of 26% was lower than management guidance, the results show substantial reductions in the cost-base and lower losses. Management note that recent order wins are likely to result in high double digit revenue growth during H117 and the company approaching EBITDA breakeven. We are withdrawing our estimates and valuation until the interims when there should be more clarity on test programmes converting to sales.

Quantum Genomics

QGC001 clinical results

Update | Pharmaceutical & healthcare | 27 Jun 2017

Quantum Genomics announced the results from the 34-patient Phase IIa study of QGC001 for the treatment of mild to moderate arterial hypertension. It showed a 2.7 mmHg placebo-adjusted reduction in the primary endpoint of ambulatory systolic blood pressure (SBP, p=0.16) and a 4.7 mmHg reduction in in-office SBP (p=0.15). The p value improved to p=0.06 using a multivariate analysis, which is encouraging given the trial size, albeit slightly non-significant. Data from this study will be used in the design of the US-based Phase IIb hypertension trial, starting in H217.

Quantum Genomics

NEW-HOPE data to be presented at AHA

Update | Pharmaceutical & healthcare | 09 Oct 2018

Quantum Genomics has announced that the results of its Phase IIb NEW-HOPE study will be presented in a late-breaking presentation at the American Heart Association (AHA) annual meeting on 10 November 2018. Late-breaking presentations are typically reserved for results that are of high interest or impact and this presentation will help increase the profile of both Quantum Genomics and firibastat with physicians, potential partners and investors. We view it as positive that the trial enrolled much faster than expected and that the results will be presented at AHA in a late-breaking presentation.

Quantum Genomics

NEW-HOPE enrolled much faster than expected

Update | Pharmaceutical & healthcare | 10 Sep 2018

Quantum Genomics announced that it has enrolled the NEW-HOPE trial faster than expected, with data to come around mid-November (previously around the end of Q119). In our opinion, the faster enrolment rate is positive as this is an open-label trial and hence we suspect that results seen by physicians to date are encouraging. As a reminder, NEW-HOPE is a study of firibastat in 256 hypertensive overweight patients across 25 major US hospitals, with a primary endpoint of change from baseline in office systolic blood pressure (SBP) at week eight.

Quantum Genomics

A little company going after big indications

Outlook | Pharmaceutical & healthcare | 13 Jul 2018

Quantum Genomics is a biopharmaceutical company investigating brain aminopeptidase A inhibitors, a new class of drug, for the treatment of hypertension and heart failure. Its lead programme, firibastat (QGC001), is in a 250-patient Phase IIb study in hypertensive overweight patients with patient dosing expected to be completed by the end of 2018 and data in Q119. Another Phase IIb in 300 subjects enrolled within 24 hours after suffering acute myocardial infarction (AMI) is expected to launch by the end of 2018 with results due in H220.

Quantum Genomics

The QUORUM trial

Update | Pharmaceutical & healthcare | 28 Jun 2018

In April, Quantum Genomics announced it would be moving forward with the Phase IIb trial in heart failure and has recently announced the design of this study. The QUORUM study will assess the safety and efficacy of Quantum’s drug firibastat (QGC001) compared to ramipril (brand name Altace), an angiotensin-converting-enzyme (ACE) inhibitor, in 300 subjects enrolled within 24 hours after suffering acute myocardial infarction (AMI). The study is expected to launch by the end of 2018 with results due in H220.

Quantum Genomics

Accelerating timelines

Update | Pharmaceutical & healthcare | 23 Apr 2018

Quantum Genomics made a number of announcements when it presented its three-year strategic plan on 19 April 2018. Importantly, it is accelerating both its hypertension and heart failure programmes. The NEW-HOPE study in 250 hypertensive overweight patients is expected to complete patient dosing by the end of the year (previously Q119). It is also moving forward with the Phase IIb trial in heart failure without waiting for the final results due to the safety data seen so far and positive results in recent animal studies. The study is expected to launch in Q418 with results expected in H220.

Quantum Genomics

NEW-HOPE trial recruiting rapidly

Update | Pharmaceutical & healthcare | 04 Apr 2018

Quantum Genomics recently announced its 2017 results and updated the status of its NEW-HOPE study in 250 hypertensive overweight patients across 25 major hospitals in the US. According to the company, the study’s recruitment has been very rapid and exceeded initial projections. Final data are expected in H119. In the near term, the company is expected to announce a three-year strategic plan on 19 April.

Quantum Genomics

NEW-HOPE trial launched

Update | Pharmaceutical & healthcare | 05 Oct 2017

Quantum Genomics recently announced H117 financial results and gave a business update for the first three quarters of the year. It highlighted the results of its Phase IIa trial for QGC001 in hypertension and the launch of the NEW-HOPE study in 250 hypertensive overweight patients across 25 major hospitals in the United States. The company is expecting to complete its 75-patient Phase II study of QGC001 in heart failure by the end of the year, with data expected in H118.

Quantum Genomics

Accelerating clinical studies

Update | Pharmaceutical & healthcare | 04 Apr 2017

Quantum Genomics reported its yearly results, which highlighted the significant progress the company has made towards the commercialisation of its product, QGC001, for treatment of hypertension (HT) and heart failure (HF). In 2016, the company both completed a 34-person Phase II HT trial (results expected June 2017) and initiated a 75-person European Phase II trial examining the drug for HF (results early 2018). The company is also set up to initiate a US Phase II for HT in H217.

Quantum Genomics

The next generation of cardiac drugs

Initiation | Pharmaceutical & healthcare | 28 Nov 2016

We are initiating coverage on Quantum Genomics, a biopharmaceutical company investigating brain aminopeptidase A inhibitors, a new class of drug, for the treatment of hypertension and heart failure with a completed and an ongoing Phase IIa study, respectively. This pathway has been implicated in patients with complicated hypertension including those who are resistant to other treatments (25%) and 52% of hypertensive African Americans. We initiate with a valuation of EUR 172m.